Original Title: Several Policies of Jiading District to Promote the Development of High-Performance Medical Equipment and Precision Medicine Industries
To implement the “Shanghai Plan” for the biopharmaceutical industry and accelerate the high-quality development of the high-performance medical equipment and precision medicine industries in our district, in accordance with the work arrangements of the District Party Committee and District Government to expedite the establishment of a new system of growth drivers for high-quality development,and in accordance with the spirit of the “Implementation Opinions on Promoting the High-Quality Development of the Biopharmaceutical Industry in Jiading District” (Jiafu Fa [2020] No. 26) and the “Special Action Plan for the Development of the High-Performance Medical Equipment and Precision Medicine Industries in Jiading District (2021–2025)” (Jiafu Fa [2021] No. 10), and taking into account the actual conditions of this district, the following policies are hereby formulated.
I. Eligible Entities
This policy applies to enterprises and institutions registered and tax-registered within Jiading District that are engaged in research and development, production, sales, and services related to high-performance medical equipment, precision medicine, biopharmaceuticals, and life sciences.
II. Scope of Support
(1) Support for Technological Innovation
1. Support for Medical Device Innovation. For newly obtained Class II and Class III medical device registration certificates, grants of up to 1 million yuan and 3 million yuan, respectively, will be awarded; for products entering the special approval or priority review procedures for innovative medical devices and subsequently obtaining a medical device registration certificate, a grant of up to 2 million yuan will be awarded;For independently developed Class II and Class III medical devices that have obtained international authoritative registrations or certifications from the U.S. FDA, European CE, or the World Health Organization (WHO), a reward of up to 1 million yuan will be granted. Assistance will be provided to help enterprises connect with medical device clinical trial institutions in our district, and priority will be given in project scheduling.
2. Support for the Development of Innovative Drugs. For those obtaining clinical trial approval, a reward of up to 1 million yuan will be granted; for those completing Phase II or Phase III clinical trials, rewards of up to 1 million yuan and 2 million yuan, respectively, will be granted; for those obtaining drug registration approval, a reward of up to 2 million yuan will be granted; for those independently developing drugs and obtaining international Current Good Manufacturing Practice (cGMP) certification from the U.S. FDA, the European EMA, or other relevant authorities, a reward of up to 2 million yuan will be granted.We will assist enterprises in connecting with clinical trial institutions in our district and prioritize their project timelines.
3. Encourage the conduct of generic drug bioequivalence evaluations. Upon receiving a notice of acceptance from the National Medical Products Administration (NMPA), a reward of up to 500,000 yuan will be granted; for those passing the generic drug bioequivalence evaluation, rewards of up to 1 million yuan (for the first applicant) and 500,000 yuan will be granted, respectively. Projects conducting bioequivalence evaluation clinical trials at drug clinical trial institutions in our district will be given priority in project scheduling.
4. Encourage the development of traditional Chinese medicine (TCM) products. A reward of 100,000 yuan will be granted for each TCM product newly registered with a national geographical indication trademark or newly designated as a nationally protected geographical indication product; for traditional Chinese medical therapies newly included in the national or municipal intangible cultural heritage lists, rewards of 100,000 yuan and 50,000 yuan will be granted, respectively.
5. Support for Major Special Projects. For entities leading national or municipal-level major science and technology projects, funding will be provided equivalent to 10% of the project budget, with maximum rewards of 5 million yuan and 2 million yuan, respectively.
6. Support enterprises and institutions in developing standards. Enterprises and institutions that take the lead in formulating international, national, or industry standards for their respective sectors will receive one-time rewards of 1 million yuan, 500,000 yuan, and 200,000 yuan, respectively.
(II) Promoting the Industrialization of Innovation Outcomes
7. Support for Science and Technology Innovation Development. Enterprises are encouraged to increase R&D investment. High-tech enterprises recognized (or introduced) in the current year will receive a one-time grant of up to 200,000 yuan following recognition, based on factors such as the enterprise’s contribution, growth potential, and R&D investment. High-tech enterprises eligible for support policies under the Zhangjiang National Independent Innovation Demonstration Zone will receive a one-time grant following recognition in accordance with the Zhangjiang Special Development Fund Management Measures.
8. Encourage collaboration among medical institutions, industry, academia, and research institutes. Enterprises within the district are encouraged to collaborate with hospitals, universities, and research institutes on medical-industry-academia-research projects focused on key industrial sectors, through forms such as commissioned R&D and joint research efforts. Upon evaluation and approval, projects will receive a subsidy of up to 50% of the total investment, not exceeding 1 million yuan. A district-level platform for medical-industry-academia-research exchange will be established to facilitate regular clinical and technical exchanges and matchmaking.
9. Ensure land supply for industrial projects. Key enterprises in the district’s priority industrial sectors may receive priority support for land allocation; for high-quality existing industrial and warehouse land where an increase in floor area ratio has been approved, no additional land premiums will be charged.
(III) Promoting Rapid Industrial Development
10. Support the introduction of key enterprises and the establishment of headquarters. For key enterprises newly established or relocated to our district that demonstrate high growth potential, strong profitability, significant driving force, and substantial potential, funding will be provided in phases based on the project’s total investment at a rate of 10%, up to a maximum of 10 million yuan, taking into account their industrial driving effect and contribution to the regional economy.For Fortune Global 500 companies, enterprises ranked among China’s Top 100 Pharmaceutical Manufacturers (based on main business revenue), or domestic and international listed biopharmaceutical enterprises that establish headquarters in our district and accelerate the clustering of upstream and downstream industrial chains, priority support will be provided on a case-by-case basis.
11. Encourage the clustering of sales headquarters enterprises. For newly introduced sales headquarters enterprises that have been certified, full rewards will be granted for the first two years and half-rate rewards for the following three years, based on their contribution to the district, starting from the date of registration. For existing sales headquarters enterprises, full rewards will be granted for the first two years and half-rate rewards for the following three years, based on the incremental portion of their contribution to the district.
12. Support for enterprise scale expansion. Enterprises whose annual main business revenue exceeds 100 million, 500 million, 1 billion, or 3 billion yuan for the first time will be granted rewards of 200,000, 500,000, 1 million, or 2 million yuan, respectively.Enterprises above the designated scale that achieve an annual output value increase of 100 million yuan or more will receive a one-time reward of 100,000 yuan; those achieving an annual output value increase of 1 billion yuan or more will receive a one-time reward of 200,000 yuan. Enterprises that first meet the criteria for the designated scale and are included in the statistics will receive a one-time reward of 200,000 yuan.
13. Promote the pilot implementation of the Marketing Authorization Holder (MAH) system.Enterprises applying for the status of Marketing Authorization Holder (MAH) for pharmaceuticals or Medical Device Registrant, or transferring registration approvals to this district, will receive a reward of up to 3 million yuan, calculated as 1% of the new sales revenue generated by the new product compared to the previous year. Enterprises within the district that have obtained authorization from a pharmaceutical MAH or medical device registrant to engage in contract manufacturing (and have no investment relationship with the holder) will receive a reward of up to 2 million yuan, calculated as 0.5% of the increase in output value per product compared to the previous year.
14. Support the development of the traditional Chinese medicine (TCM) industry. Support innovative enterprises in cultivating various locally suitable medicinal herbs at the TCM trial planting base within the Shanghai International Health Industry Park, with a focus on “preventive healthcare” and leveraging the concept of “medicinal and edible dual-use” (yao-shi tongyuan). Enterprises that utilize local medicinal herb resources to develop TCM decoction pieces and TCM preparations will be granted a reward of up to 500,000 yuan.
15. Encourage improvements in production quality management. New production lines that pass Good Manufacturing Practice (GMP) certification or obtain a pharmaceutical production license will be granted a reward of up to 1 million yuan.
16. Accelerate the promotion and application of innovative products. Key hospitals and pharmaceutical wholesale and retail institutions within the district are encouraged to make initial purchases of innovative drugs and medical devices launched by local enterprises within the past two years; funding of up to 1 million yuan will be provided in the form of research grants, equivalent to 10% of the procurement amount. Manufacturers of these first-purchase products will receive a reward of up to 500,000 yuan, equivalent to 50% of their insurance premiums.
17. Support efforts to reduce enterprises’ costs for production land and facilities. Newly introduced biopharmaceutical enterprises that are officially recognized and purchase land within the district for production, R&D, or office use will be granted preferential land prices based on their project specifics, with subsidies of up to 10 million yuan (subject to compliance with relevant regulations on land transfer); for those leasing production, R&D, or office space with an area of 500 square meters or more, a subsidy of 30% of the lease price will be provided for three years, with a cumulative maximum of 3 million yuan over the three-year period.
(IV) Support for Platform Development
18. Support for the development of public service platforms. For newly established public service platforms—including third-party testing services for drugs and medical devices, GMP shared laboratories, laboratory animal services, drug screening, pharmacology and toxicology research, efficacy evaluation, and new drug approval services—a subsidy of up to 1 million yuan, equivalent to 30% of the total project investment, will be provided.For various types of technological innovation service platforms and specialized service platforms recognized by municipal-level or higher competent authorities, a subsidy of up to 2 million yuan, equivalent to 30% of the total project investment, will be provided. For public service platforms that have been established and are in operation, providing specialized services to enterprises within the district (with no investment relationship), a reward of up to 5 million yuan, equivalent to 10% of the annual service revenue, will be granted.
19. Accelerate the development of specialized technical platforms. For newly introduced industry-leading specialized technical platforms in the biopharmaceutical sector—such as Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Contract Development and Manufacturing Organizations (CDMOs)—a reward of up to 5 million yuan will be provided, equivalent to 10% of the contract value.
20. Support the construction of medical research centers. Encourage collaborative efforts to build medical-engineering innovation platforms, clinical sample repositories, health big data platforms, and platforms for clinical trials of drugs and medical devices. A reward of up to 3 million yuan, equivalent to 20% of the total project investment, will be granted.
21. Encourage enterprises to cluster in industrial parks.For park operating companies that meet annual targets, a reward of 10% of the incremental contribution made by enterprises within the park to the district will be granted, up to a maximum of 5 million yuan. Relevant entities are encouraged to collaborate with key domestic and international research institutes, universities, medical institutions, and R&D organizations to establish biopharmaceutical industrial parks in the district, engaging in park development and operation, project attraction, and technology commercialization. Upon approval, funding equivalent to 20% of the fixed-asset investment will be provided, up to a maximum of 20 million yuan.
(5) Optimizing the Development Environment
22. Establish and improve a support mechanism. Provide comprehensive support and services during registration, approval, and other procedures. Implement “one-on-one” full-process services for the approval procedures of major industrial projects to minimize approval time and accelerate project construction.
23. Prioritize the inclusion of enterprise products in the medical insurance directory. Actively encourage enterprises to participate in national centralized drug procurement pilot programs.
24. Strengthen Talent Recruitment and Development. Support and guide higher education institutions and social training organizations to establish majors, courses, and vocational skills training programs related to key industrial sectors; build relevant internship, practical training, and experimental platforms; and carry out school-enterprise cooperation, industry-education integration, and industry-academia-research collaboration. Strengthen major development and the cultivation of practical talent, and establish talent training bases.Quotas for special talent residency permits shall be prioritized for talent in key industrial sectors; for scarce and specialized talent recruited by enterprises in key industrial sectors, priority shall be given to applying for additional points on residence permits and shortening the residency-to-household registration period; priority shall be given to accessing public rental housing, talent apartments, and talent housing subsidy policies; and priority shall be given to accessing the benefits outlined in the district and town Elite Talent Service Card policy.Leverage the role of public employment and talent service agencies to prioritize providing talent residency registration, school-enterprise cooperation, and public recruitment services to enterprises in key industrial sectors; encourage social entities to focus on attracting high-level domestic and international talent in key industrial sectors. Highly skilled talent recruited by employers in key industrial sectors who have received honors such as the China Skills Grand Prize or the National Technical Expert title may directly apply for permanent residency in this city.
25. Establish a mechanism to facilitate import and export clearance. Implement categorized regulatory measures for the import and export of biopharmaceutical R&D enterprises, their R&D products, and goods used for R&D, and establish and improve a joint regulatory mechanism.
26. Support green development.The district will coordinate the total pollutant emission quotas for biopharmaceutical enterprises. Support will be provided for micro, small, and incubator-type biopharmaceutical R&D projects; upon obtaining environmental impact assessment (EIA) approval and completing acceptance filing, a subsidy of up to 20,000 yuan will be granted, covering 50% of the EIA service fees. Standardized collection, sorting, temporary storage, and disposal of hazardous waste will be encouraged; for small and medium-sized enterprises (SMEs) engaged in biopharmaceutical R&D and production, a subsidy of up to 50,000 yuan will be provided, covering 50% of hazardous waste disposal costs, with support lasting for three years.We encourage the enhancement of hazardous waste disposal facilities. For hazardous waste collection construction projects implemented by specialized industrial parks, a subsidy of up to 1 million yuan, equivalent to 30% of the project investment, will be provided upon obtaining an operating license. For hazardous waste self-utilization and disposal construction projects implemented by enterprises, a subsidy of up to 500,000 yuan, equivalent to 30% of the project investment, will be provided upon successful acceptance.
27. Increase fund support for industrial projects. Establish special investment funds for key industries to focus on investing in related sectors. Encourage domestic and international venture capital funds, investment companies, listed companies, and other institutions to establish investment entities in Jiading District that primarily target key industries.
28. Strengthen financial support. Support financial institutions in providing financial services—such as loan risk compensation mechanisms, financing guarantees, and interest and fee subsidies—to enterprises in key industries. For guarantee institutions within Jiading District that provide guarantees, a subsidy of 1.5% of the annual guarantee amount will be provided, with a maximum subsidy of 5 million yuan. For enterprises in key industries that successfully complete shareholding reform and list on a stock exchange, a one-time subsidy of up to 2 million yuan will be provided in addition to the district’s existing listing subsidy policies.For newly established projects related to key industries, a 2-percentage-point annual interest subsidy will be provided on the verified portion of bank loans required for project construction, with a maximum subsidy of 5 million yuan per year, for a consecutive period of three years. Support will be provided to enterprises in key industries to restructure and integrate upstream and downstream industrial chains through activities such as mergers and acquisitions; relevant district industrial investment funds may participate jointly or provide financial support.
III. Supplementary Provisions
1. In principle, the support measures under this policy shall be implemented in accordance with the development directions specified in the “Implementation Opinions on Promoting the High-Quality Development of the Biomedical Industry in Jiading District.”
2. “Newly introduced enterprises” under this policy refer to enterprises newly introduced after January 1, 2021, with their tax administration jurisdiction located in our district.
3. For major projects approved by the District Government, the support ratio and funding amount are not subject to the above standards; such projects will receive priority support on a case-by-case basis.
4. All projects under this policy shall follow a “first-come, first-served” application and reimbursement process. If an enterprise has already received support for the same project under other district or town industrial policies, the principle of “selecting the highest amount without duplication and avoiding duplication for individual items” shall apply.
5. The District Economic Commission, in conjunction with relevant departments, will comprehensively evaluate factors such as the applicant enterprise’s economic contribution, technological innovation, social integrity, energy conservation and environmental protection, and workplace safety. Enterprises that committed major violations of laws or discipline, or engaged in other serious acts of dishonesty in the year preceding the application year will be disqualified from receiving support for the current year.
6. During the trial implementation of this policy, if new policies are issued by the state, the municipality, or the district, such policies shall be implemented in accordance with the relevant provisions. If significant changes occur in the industry environment during the implementation of this policy, the District Economic Commission, in conjunction with relevant departments, shall study and adjust industry support standards and policies, and publish them in the form of application guidelines.
7. This policy shall be jointly interpreted by the Jiading District Economic Commission, the Jiading District Development and Reform Commission, the Jiading District Science and Technology Commission, the Jiading District Health Commission, the Jiading District Finance Bureau, and the Jiading District Market Supervision Administration.
8. This policy shall take effect on July 1, 2021, and remain valid for three years.
